Western blot analyses showed that infigratinib-resistant HCC21-0208, HCC06-0606, and HCC01-0909 tumours constitutively express higher levels of p-EGFR, p-ErbB2, and p-ErbB3 (Fig. 2B). This evidence concerns the gene EGFR and neoplasm.